You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 296 No. 1, July 5, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Cardiovascular System
 •Cardiovascular Disease/ Myocardial Infarction
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Medical Management of Peripheral Arterial Disease

Since this article does not have an abstract, we have provided the first 141 words of the full text and any section headings.

To the Editor: In discussing medical treatment of PAD, Dr Hankey and colleagues1 state that "a meta-analysis of 8 [randomized controlled trials] involving 2702 patients demonstrated that cilostazol improved maximum walking distance and pain-free walking distance," citing Thompson et al.2 However, in that study, the effect size was small, with increases of 50% and 67% in maximum walking distance and pain-free walking distance, respectively. Stated differently, if a patient could walk to first base before experiencing claudication, then with the addition of cilostazol, with its potential toxicity and at a cost in our pharmacy of $467.78 per month, he or she could round first and make it part of the way to second base.

Addressing effect size and cost data could help clinicians improve decision-making beyond a simple assertion of a drug's effectiveness for treating the condition.

Financial Disclosures: None reported.

Thomas E. Finucane, MD
tfinucane@jhmi.edu
Geriatric Center
Johns Hopkins Bayview Medical Center
Baltimore, Md

1. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295:547-553. FREE FULL TEXT
2. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo controlled trials, on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90:1314-1319. FULL TEXT | WEB OF SCIENCE | PUBMED

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;296:41.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Medical Management of Peripheral Arterial Disease
Daniel G. Hackam
JAMA. 2006;296(1):41.
EXTRACT | FULL TEXT  

Medical Management of Peripheral Arterial Disease—Reply
John Eikelboom, Graeme Hankey, and Paul Norman
JAMA. 2006;296(1):41-42.
EXTRACT | FULL TEXT  

Medical Treatment of Peripheral Arterial Disease
Graeme J. Hankey, Paul E. Norman, and John W. Eikelboom
JAMA. 2006;295(5):547-553.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.